

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|------------|---|---|---|----------------|
| Applicants | : | Miller et al. |) | Examiner: |
| | | |) | To Be Assigned |
| Serial No. | : | Division of 10/106,521 |) | |
| | | |) | Art Unit: |
| Cnfrm. No. | : | To Be Assigned |) | To Be Assigned |
| | | |) | |
| Filed | : | Herewith |) | |
| | | |) | |
| For | : | YOHIMBINE DIMERS EXHIBITING BINDING |) | |
| | | SELECTIVITIES FOR α_2 ADRENERGIC |) | |
| | | RECEPTORS |) | |

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

Mail Stop: Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.98(d), the references identified on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the PTO in parent U.S. Patent Application Serial No. 10/106,521, filed March 25, 2002, of which this application claims priority under 35 USC § 120.

Respectfully submitted,

Date: October 6, 2003


Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600

| | | |
|--|---|---|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449) | ATTY. DOCKET NO. 20609/203 (PD 00034) | SERIAL NO. Division of 10/106,521 |
| | APPLICANT Miller et al. | |
| | FILING DATE Herewith | GROUP ART UNIT To be Assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|---|--------------------|------------|------------------|-------|----------|--|
| | 1 | 3,940,387 | 02/24/1976 | Saint-Ruf et al. | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS- LATION IF APPRO- PRIATE |
|--|--|--------------------|------|---------|-------|----------|--|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|---|--|---|--|
| | | 2 | Portoghese et al., "Stereostructure-Activity Relationship of Opioid Agonist and Antagonist Bivalent Ligands. Evidence for Bridging Between Vicinal Opioid Receptors," <u>J. Med. Chem.</u> 28:1140-41 (1985) |
| | | 3 | Erez et al., "Narcotic Antagonist Potency of Bivalent Ligands Which Contain β -Naltrexamine. Evidence for Bridging Between Proximal Recognition Sites," <u>J. Med. Chem.</u> 25:847-849 (1982) |
| | | 4 | Philip S. Portoghese, "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands," <u>Journal of Medicinal Chemistry</u> 35(11):1927-1937 (1992) |
| | | 5 | Philip S. Portoghese, "Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists," <u>TIPS Review</u> 10:230-235 (1989) |
| | | 6 | Shimohigashi et al., "Dimeric Tetrapeptide Enkephalins Display Extraordinary Selectivity for the δ Opiate Receptor," <u>Nature</u> 297:333-335 (1982) |
| | | 7 | LeBoulluec et al., "Bivalent Indoles Exhibiting Serotonergic Binding Affinity," <u>Bioorganic & Medicinal Chemistry Letters</u> , 5:123-126 (1995) |
| | | 8 | Cwirla et al., "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <u>Science</u> 276:1696-1699 (1997) |
| EXAMINER | | | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

| | | |
|--|---|---|
| U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449) | ATTY. DOCKET NO. 20609/203 (PD 00034) | SERIAL NO. Division of 10/106,521 |
| | APPLICANT Miller et al. | |
| | FILING DATE Herewith | GROUP ART UNIT To be Assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|--|--------------------|------|------|-------|----------|--|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANS- LATION IF APPRO- PRIATE |
|--|--|--------------------|------|---------|-------|----------|--|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

| | | | |
|---|--|----|---|
| | | 9 | Uhlén et al., "Membrane Organization and Mobility of α_2 Adrenergic Receptors in MDCK Cells," <u>Pharmacology Communications</u> 6(1-3):155-167 (1995) |
| | | 10 | Maggio et al., "Coexpression Studies with Mutant Muscarinic/Adrenergic Receptors Provide Evidence for Intermolecular "Cross-Talk" Between G-Protein-Linked Receptors," <u>Proc. Natl. Acad. Sci. USA</u> 90:3103-3107 (1993) |
| | | 11 | Maggio et al., "Functional Role of the Third Cytoplasmic Loop in Muscarinic Receptor Dimerization," <u>The Journal of Biological Chemistry</u> 271(49):31055-31060 (1996) |
| | | 12 | Zheng, et al., "Yohimbine Dimers Exhibiting Binding Selectivities for Human α_{2a} - versus α_{2b} -Adrenergic Receptors," <u>Biorg. Med. Chem. Lett.</u> 10:627-630 (2000) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| EXAMINER | | | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |